On December 30, 2021, Nanhua Bio-Medicineco.Ltd(000504) held the year-end summary meeting of 2021 and the work planning meeting of 2022.
At the meeting, Nanhua Bio-Medicineco.Ltd(000504) general manager you Changqiao made an annual summary report. In 2021, the epidemic of covid-19 pneumonia spread all over the world. Facing difficulties and challenges, Nanhua Bio-Medicineco.Ltd(000504) has always been firm in the company’s strategic positioning, worked together to overcome difficulties, and made a series of achievements in the establishment of expert scientific research team, clinical scientific research technology reserve, cell preparation process improvement, marketing team building, etc.
You Changqiao summarized the whole year and planned the coming year from the three levels of “bottom line thinking”, “strategic positioning” and “result orientation”.
——The bottom line of Nanhua Bio-Medicineco.Ltd(000504) is to put life first and protect health. ” Nanhua Bio-Medicineco.Ltd(000504) as the only listed company on the main board of stem cell, immune cell and tissue engineering controlled by state-owned assets in China, it has made continuous efforts to improve the health level of the people.” fraternity, health and benefit the public “is a correct choice for our company to adapt to the development of commercial civilization in the new era”;
——It is the strategy of Nanhua Bio-Medicineco.Ltd(000504) to change everything. In 2021, Nanhua Bio-Medicineco.Ltd(000504) continued reform and innovation, established a passionate and dynamic R & D team with Zhou Honghao, academician of the Chinese Academy of engineering, as the chairman of the expert committee, built many innovation platforms for the transformation of clinical scientific research achievements and the improvement of cell preparation process, such as Hunan biomedical science and Technology Collaborative Innovation Center, and improved the layout of the company in the big health industry chain, It has explored a new business model and made a major breakthrough in cell clinical scientific research and technical reserve.
——The road is blocked and long, and the line is coming. It is the goal of Nanhua Bio-Medicineco.Ltd(000504) . In 2022, facing the complex and severe situation of the industry, Nanhua Bio-Medicineco.Ltd(000504) all employees will adhere to the business philosophy of “striving for excellence and reaching the world”, and contribute to Nanhua Bio-Medicineco.Ltd(000504) becoming a “top biotechnology company in the world”.
You Changqiao, general manager of Nanhua Bio-Medicineco.Ltd(000504) : let’s believe in the power of goodness
Colleagues, partners and friends of Nanhua Bio-Medicineco.Ltd(000504) :
hello everyone! The new year is coming quietly. In 2021, Nanhua Bio-Medicineco.Ltd(000504) has made great progress and development with the support and help of governments at all levels, Caixin financial holding, shareholders and directors of the company and the joint efforts of colleagues of the company. On behalf of Nanhua Bio-Medicineco.Ltd(000504) , I would like to extend my cordial condolences and sincere thanks to all colleagues of the company who are brave and enterprising!
In 2021, the epidemic of covid-19 pneumonia spread all over the world. In the face of difficulties and challenges, we have always been firm in the company’s strategic positioning, unswervingly focused and overcome difficulties. The company has made certain achievements in the establishment of expert scientific research team, clinical scientific research technology reserve, improvement of cell preparation process and building of marketing team, which has taken a solid step for the high-quality development of the company. These achievements embody the perseverance and selfless dedication of every South Chinese. I am grateful for this! For this year’s summary and expectations for the coming year, I mainly want to express three points.
I. “bottom line thinking”
Life is supreme and protecting health is our bottom line. Human health is not only the basis of social civilization and progress, but also the eternal pursuit of companies engaged in biomedical industry. “Take out a little water and you can build a new forest” can be properly compared to the stem cell therapy industry, which is an industry in the life cycle of disruptive breakthrough and represents the trend of medical development in the future. Nanhua Bio-Medicineco.Ltd(000504) as the only listed company on the main board of stem cell, immune cell and tissue engineering controlled by state-owned assets in China, we make continuous efforts to improve the health level of the people. “Fraternity, health and benefit the public” is a correct choice for our company to adapt to the development of commercial civilization in the new era. All take public health as the basic starting point and fundamental direction. Only by solving directional problems and establishing a “community of destiny” with society can enterprises truly realize sustainable development.
The outline of the “healthy China 2030” plan clearly points out that we should promote the construction of a healthy China, strengthen the institutional guarantee for improving people’s health level, adhere to prevention first, and steadily develop the public health service system. In the historical process of realizing the “two centenary” goals, the development of health care has always been in a fundamental position, closely linked with the overall national strategy and played an important supporting role. In 2021, Nanhua Bio-Medicineco.Ltd(000504) will cooperate with the Red Cross Foundation of China to build fraternity primary health stations, promote rural revitalization and achieve common prosperity. To meet their desire for a happy life is our mission. Today, with the rapid development of Nanhua Bio-Medicineco.Ltd(000504) , we still will not forget to give back to the people and society. Enterprises drive the people to get rich. The people support the development of enterprises, trust and support each other, so that Nanhua Bio-Medicineco.Ltd(000504) can have a deeper and broader development space in the future.
II. “Strategic focus”
It is our strategy to change and not follow. The next 10 years will be an important period of strategic opportunity to promote the construction of a healthy China. The development of stem cells, regenerative medicine, biotherapy and other medical cutting-edge technologies has become an important part of the national strategy. For enterprises engaged in the stem cell industry, it is undoubtedly an epoch-making signal release. After so many years of persistence, so many years of persistence and so many years of courage to challenge, there will be explosive results.
If you want to grow up, you must first take root down. In 2021, we continued to reform and innovate, established a passionate and dynamic R & D team with Zhou Honghao, academician of the Chinese Academy of engineering, as the chairman of the expert committee, built many innovation platforms for the transformation of clinical scientific research achievements and the improvement of cell preparation process, such as Hunan biomedical science and Technology Collaborative Innovation Center, and improved the layout of the company in the big health industry chain, It has explored a new business model and made a major breakthrough in cell clinical research and technical preparation. These achievements have been highly concerned by industry leaders, experts and customers, demonstrated Nanhua style, improved the corporate image, and steadily improved Nanhua Bio-Medicineco.Ltd(000504) influence, popularity and brand strength.
III. “result oriented”
The road is blocked and long, and the line is coming, which is our goal. Where does the enterprise stand? With results, with results! Our way of action directly determines the success or failure of the results. We should start from the details, be down-to-earth, keep our words and do our deeds! Executive ability is the ability to complete work tasks with quality and quantity, and it is the ability we must have to do a good job.
The innovation needed by the biomedical industry is “true innovation”. In order to solve the subversive innovation of clinical needs, it must not only lead in China, but must be an innovation at the forefront of the world. The scientific researchers of the company should have a strong enterprising spirit and a high sense of responsibility. I believe Nanhua Bio-Medicineco.Ltd(000504) will take a solid step in the high-quality take-off in the field of stem cell regenerative medicine technology innovation and stem cell industrialization, and lead the first echelon of cell industry.
In 2022, in the face of the complex and severe situation in the industry, the company should continue to maintain strategic concentration and historical patience. According to the established objectives, the company should interpret responsibility with hard work and performance with promising performance, unswervingly do the immediate things, do the long-term things, carry forward the fighting spirit of “brave and fearless”, never forget the original intention, forge ahead and win opportunities for the development of the next year.
No matter how high the mountain is, you can always climb to the top; No matter how long the road is, you will reach it. It is hoped that all employees can adhere to the business philosophy of “striving for excellence and reaching the world with virtue”, do their own work well, cultivate opportunities in the crisis, open a new situation in the changing situation, seize opportunities, respond to challenges, move forward hand in hand, contribute to Nanhua Bio-Medicineco.Ltd(000504) becoming a “top biotechnology company in the world”, and make unremitting efforts to realize the unity of life ideal and social ideal, To successfully complete the “enterprise dream” and “China dream” in the new century!
Finally, I wish the great motherland more prosperity! Wish Nanhua Bio-Medicineco.Ltd(000504) a more prosperous career! I wish every South Chinese family happiness, good luck and physical and mental health!
Let us believe in the power of good.
Nanhua Bio-Medicineco.Ltd(000504) you Changqiao, general manager
January 1, 2022
(Palm Changsha)
